Astex Pharmaceuticals , 436 Cambridge Science Park , Cambridge CB4 0QA , U.K.
GlaxoSmithKline , 1250 South Collegeville Road , Collegeville , Pennsylvania 19426-0989 , United States.
J Med Chem. 2019 May 9;62(9):4683-4702. doi: 10.1021/acs.jmedchem.9b00279. Epub 2019 Apr 25.
The KEAP1-NRF2-mediated cytoprotective response plays a key role in cellular homoeostasis. Insufficient NRF2 signaling during chronic oxidative stress may be associated with the pathophysiology of several diseases with an inflammatory component, and pathway activation through direct modulation of the KEAP1-NRF2 protein-protein interaction is being increasingly explored as a potential therapeutic strategy. Nevertheless, the physicochemical nature of the KEAP1-NRF2 interface suggests that achieving high affinity for a cell-penetrant druglike inhibitor might be challenging. We recently reported the discovery of a highly potent tool compound which was used to probe the biology associated with directly disrupting the interaction of NRF2 with the KEAP1 Kelch domain. We now present a detailed account of the medicinal chemistry campaign leading to this molecule, which included exploration and optimization of protein-ligand interactions in three energetic "hot spots" identified by fragment screening. In particular, we also discuss how consideration of ligand conformational stabilization was important to its development and present evidence for preorganization of the lead compound which may contribute to its high affinity and cellular activity.
KEAP1-NRF2 介导的细胞保护反应在细胞内稳态中起着关键作用。在慢性氧化应激过程中,如果 NRF2 信号不足,可能与具有炎症成分的几种疾病的病理生理学有关,并且通过直接调节 KEAP1-NRF2 蛋白-蛋白相互作用来激活该途径,正逐渐被探索作为一种潜在的治疗策略。然而,KEAP1-NRF2 界面的物理化学性质表明,实现对穿透细胞的类药抑制剂的高亲和力可能具有挑战性。我们最近报道了一种高活性的工具化合物的发现,该化合物用于探测与直接破坏 NRF2 与 KEAP1 Kelch 结构域相互作用相关的生物学。我们现在详细介绍了导致该分子的药物化学研究进展,其中包括通过片段筛选鉴定的三个能量“热点”来探索和优化蛋白-配体相互作用。特别是,我们还讨论了配体构象稳定化的考虑因素对其发展的重要性,并提供了关于先导化合物预组织的证据,这可能有助于其高亲和力和细胞活性。